Signe Sørensen Torekov

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/851297/publications.pdf

Version: 2024-02-01

47 papers

2,408 citations

331670 21 h-index 223800 46 g-index

48 all docs

48 docs citations

48 times ranked

4014 citing authors

#	Article	IF	CITATIONS
1	Low Physical Activity Accentuates the Effect of the <i>FTO</i> rs9939609 Polymorphism on Body Fat Accumulation. Diabetes, 2008, 57, 95-101.	0.6	431
2	GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study. Diabetes, 2015, 64, 2513-2525.	0.6	235
3	Proteomics reveals the effects of sustained weight loss on the human plasma proteome. Molecular Systems Biology, 2016, 12, 901.	7.2	188
4	Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. New England Journal of Medicine, 2021, 384, 1719-1730.	27.0	171
5	Insulin Resistance Is Accompanied by Increased Fasting Glucagon and Delayed Glucagon Suppression in Individuals With Normal and Impaired Glucose Regulation. Diabetes, 2016, 65, 3473-3481.	0.6	137
6	GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2909-2917.	3.6	116
7	Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist. Cell Metabolism, 2018, 28, 23-32.e3.	16.2	88
8	Plasma Proteome Profiling Reveals Dynamics of Inflammatory and Lipid Homeostasis Markers after Roux-En-Y Gastric Bypass Surgery. Cell Systems, 2018, 7, 601-612.e3.	6.2	80
9	Evidence of a liver–alpha cell axis in humans: hepatic insulin resistance attenuates relationship between fasting plasma glucagon and glucagonotropic amino acids. Diabetologia, 2018, 61, 671-680.	6.3	76
10	Successful weight loss maintenance includes long-term increased meal responses of GLP-1 and PYY3–36. European Journal of Endocrinology, 2016, 174, 775-784.	3.7	72
11	Glucagon acutely regulates hepatic amino acid catabolism and the effect may be disturbed by steatosis. Molecular Metabolism, 2020, 42, 101080.	6.5	66
12	KCNQ1 Long QT Syndrome Patients Have Hyperinsulinemia and Symptomatic Hypoglycemia. Diabetes, 2014, 63, 1315-1325.	0.6	61
13	Fat-Secreted Ceramides Regulate Vascular Redox State and Influence Outcomes in Patients With Cardiovascular Disease. Journal of the American College of Cardiology, 2021, 77, 2494-2513.	2.8	59
14	Association between Neuromedin U Gene Variants and Overweight and Obesity. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 5057-5063.	3.6	54
15	Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential. Obesity Reviews, 2011, 12, 593-601.	6.5	50
16	Glucose-Dependent Insulinotropic Polypeptide Is Associated With Lower Low-Density Lipoprotein But Unhealthy Fat Distribution, Independent of Insulin: The ADDITION-PRO Study. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 485-493.	3.6	46
17	Therapies for inter-relating diabetes and obesity – GLP-1 and obesity. Expert Opinion on Pharmacotherapy, 2014, 15, 2487-2500.	1.8	37
18	Sperm count is increased by diet-induced weight loss and maintained by exercise or GLP-1 analogue treatment: a randomized controlled trial. Human Reproduction, 2022, 37, 1414-1422.	0.9	34

#	Article	IF	Citations
19	Evidence of an Association Between the Arg72 Allele of the Peptide YY and Increased Risk of Type 2 Diabetes. Diabetes, 2005, 54, 2261-2265.	0.6	33
20	Patients With Long-QT Syndrome Caused by Impaired <i>hERG</i> -Encoded K _v 11.1 Potassium Channel Have Exaggerated Endocrine Pancreatic and Incretin Function Associated With Reactive Hypoglycemia. Circulation, 2017, 135, 1705-1719.	1.6	33
21	Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB. Obesity Science and Practice, 2017, 3, 425-433.	1.9	25
22	Instrumentalization of Eating Improves Weight Loss Maintenance in Obesity. Obesity Facts, 2017, 10, 633-647.	3.4	23
23	Health care professionals from developing countries report educational benefits after an online diabetes course. BMC Medical Education, 2017, 17, 97.	2.4	23
24	Effects of vegan diets on cardiometabolic health: A systematic review and metaâ€analysis of randomized controlled trials. Obesity Reviews, 2022, 23, .	6.5	23
25	Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists. Drug Safety, 2019, 42, 957-971.	3.2	22
26	GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report. Cell Reports Medicine, 2020, 1, 100006.	6.5	22
27	Dose response of subcutaneous GLP-1 infusion in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2011, 13, 639-643.	4.4	21
28	Glucagon-Like Peptide 1: A Predictor of Type 2 Diabetes?. Journal of Diabetes Research, 2017, 2017, 1-13.	2.3	21
29	Family and Population-Based Studies of Variation within the Ghrelin Receptor Locus in Relation to Measures of Obesity. PLoS ONE, 2010, 5, e10084.	2.5	18
30	Homozygous carriers of the G allele of rs4664447 of the glucagon gene (GCG) are characterised by decreased fasting and stimulated levels of insulin, glucagon and glucagon-like peptide (GLP)-1. Diabetologia, 2011, 54, 2820-2831.	6.3	16
31	Protocol for a single-centre, parallel-group, randomised, controlled, superiority trial on the effects of time-restricted eating on body weight, behaviour and metabolism in individuals at high risk of type 2 diabetes: the REStricted Eating Time (RESET) study. BMJ Open, 2020, 10, e037166.	1.9	13
32	Major rapid weight loss induces changes in cardiac repolarization. Journal of Electrocardiology, 2016, 49, 467-472.	0.9	12
33	Common variants in the hERG (KCNH2) voltage-gated potassium channel are associated with altered fasting and glucose-stimulated plasma incretin and glucagon responses. BMC Genetics, 2018, 19, 15.	2.7	12
34	Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet. BMJ Open, 2019, 9, e031431.	1.9	11
35	Age-dependent transition from islet insulin hypersecretion to hyposecretion in mice with the long QT-syndrome loss-of-function mutation Kcnq1-A340V. Scientific Reports, 2021, 11, 12253.	3.3	10
36	A Gut-Intrinsic Melanocortin Signaling Complex Augments L-Cell Secretion in Humans. Gastroenterology, 2021, 161, 536-547.e2.	1.3	10

#	Article	IF	CITATIONS
37	No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes: A post hoc analysis from the randomized controlled ⟨scp⟩PREâ€D⟨/scp⟩ trial. Diabetes, Obesity and Metabolism, 2021, 23, 530-539.	4.4	9
38	Glucose ingestion causes cardiac repolarization disturbances in type $1\ \text{long}\ \text{QT}$ syndrome patients and healthy subjects. Heart Rhythm, 2017, 14, 1165-1170.	0.7	8
39	Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures. Cardiovascular Diabetology, 2019, 18, 130.	6.8	8
40	Adults with pathogenic MC4R mutations have increased final height and thereby increased bone mass. Journal of Bone and Mineral Metabolism, 2020, 38, 117-125.	2.7	7
41	Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL. Cardiovascular Research, 2018, 114, e70-e71.	3.8	6
42	Gain-of-function mutation in the voltage-gated potassium channel gene KCNQ1 and glucose-stimulated hypoinsulinemia - case report. BMC Endocrine Disorders, 2020, 20, 38.	2.2	6
43	Celebrities in the heart, strangers in the pancreatic beta cell: Voltageâ€gated potassium channels K _v 7.1 and K _v 11.1 bridge long QT syndrome with hyperinsulinaemia as well as type 2 diabetes. Acta Physiologica, 2022, 234, e13781.	3.8	6
44	Habitual physical activity is associated with lower fasting and greater glucose-induced GLP-1 response in men. Endocrine Connections, 2019, 8, 1607-1617.	1.9	5
45	Glucagon-like peptide-1 receptor agonists: the key to healthy weight loss maintenance?. Cardiovascular Research, 2021, 117, e120-e122.	3.8	3
46	Response to Comment on Færch et al. GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study. Diabetes 2015;64:2513–2525. Diabetes, 2015, 64, e30-e31.	0.6	1
47	Weight loss and weight maintenance obtained with or without GLP-1 analogue treatment decrease branched chain amino acid levels. Metabolomics, 2016, 12, 1.	3.0	o